ClinicalTrials.gg
Not yet recruitingNCT07645547Updated Jun 12, 2026

Prophylactic Use of ciNPWT in Gynecologic Laparotomy

An interventional study of closed incision negative pressure wound therapy (ciNPWT) in Surgical Site Infection (SSI), Wound Healing Complication and Seroma, sponsored by University Hospital Hradec Kralove. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-12.

Sponsored by University Hospital Hradec Kralove · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is a prospective, open-label, non-randomized interventional feasibility study with a nested qualitative analysis. The study exploratively verifies the feasibility of targeted prophylactic closed incision negative pressure wound therapy (ciNPWT) in clinical practice for patients with a high predicted risk of wound healing complications and compares the 30-day incidence of postoperative complications with standard dressing.

Participants will:

  • Get ciNPWT or standard dressing after planned laparotomy
  • Answer the questionairs about qualite of life
  • Will visit the clinic 30 days after surgery to see the final result
02

Conditions studied

  • Surgical Site Infection (SSI)
  • Wound Healing Complication
  • Seroma
  • Hematoma
  • Dehiscence

Keywords

  • ciNPWT
  • laparotomy
  • surgical site infection
  • SSI
  • feasibility
  • PROMs
  • ASEPSIS
03

In context

Surgical Wound Infection

745 studies on the registry are indexed under Surgical Wound Infection; 151 are open to participants now.

This study's planned enrollment of 30 is below the median of 200 across 581 interventional studies indexed under Surgical Wound Infection.

Browse Surgical Wound Infection studies →

Lead sponsor

University Hospital Hradec Kralove is the lead sponsor of 49 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female patients scheduled for planned abdominal surgery for gynecologic or gynecologic-oncologic indications.

Identification as "high-risk" for wound healing complications based on a clinical risk screening at admission.

Signed .

Exclusion criteria

Exclusion Criteria:

  • Failure to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Preventive ciNPWT

    Device: closed incision negative pressure wound therapy (ciNPWT)

  • No intervention
    Standard dressing

Interventions

  • Deviceclosed incision negative pressure wound therapy (ciNPWT)

    targeted prophylactic closed incision negative pressure wound therapy in clinical practice for patients with a high predicted risk of wound healing complications

06

What researchers measure

Primary outcomes

  1. Feasibility of targeted prophylactic ciNPWT

    Feasibility of prophylactic ciNPWT described as: Recruitment rate (%)

    Time frame: Up to 30 postoperative days

  2. Feasibility of targeted prophylactic ciNPWT

    Feasibility of prophylactic ciNPWT described as: Completion rate (%)

    Time frame: Up to 30 postoperative days

  3. Feasibility of targeted prophylactic ciNPWT

    Feasibility of prophylactic ciNPWT described as: Safety and technical complications (description)

    Time frame: Up to 30 postoperative days

Secondary outcomes

  1. Objective assessment of wound healing

    Objective assessment of wound healing using the ASEPSIS (Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the deep tissues, the Isolation of bacteria, and the duration of inpatient Stay = ASEPSIS) scoring system (scale 0-100, higher number = worse outcome).

    Time frame: Up to 30 postoperative days.

  2. Subjective assessment of pain

    Pain assessment using the Numeric Rating Scale (NRS, scale 0-10, higher number = worse outcome) at rest and during movement.

    Time frame: Up to 30 postoperative days

  3. Subjective assessment of quality of life

    Patient-Reported Outcomes including the 5-level version of Quality of life EuroQol Group questionnaire (EQ-5D-5L, scale 5-25, higher number = worse outcome).

    Time frame: Up to 30 postoperative days

  4. Subjective treatment satisfaction

    Treatment satisfaction and patient experience via an original questionnaire (scale 8-40, higher number = worse outcome).

    Time frame: Up to 30 postoperative days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2028, 23 months later.

Of 201 non-industry interventional studies with no phase under Surgical Wound Infection, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 23 months is close to that.

Counting every sponsor, half of 208 studies reached it within 24 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2026
First posted
Jun 12, 2026
StartEst.
Jul 2026
Primary completionEst.
Jun 2028
CompletionEst.
Dec 2028
Last update
Jun 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07645547
Lead sponsor
University Hospital Hradec Kralove
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jul 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 12, 2026

Study contacts

Klara Balcarova
Contact
klara.balcarova@fnhk.cz
+420731964956

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion